ENOV trades at 5.5x forward P/E and ~5.6x forward EV/EBITDA against mid-single-digit organic growth, 17.9% EBITDA margin, and $430M FY26E adjusted EBITDA guidance. Stock is down ~40% YoY after the $1.05B 2025 goodwill impairment, which cleaned the balance sheet of accounting legacy from the DJO acquisition but leaves $1.26B net debt (2.9x EBITDA). Reconstructive segment is the growth engine (+6-8% organic), Prevention & Recovery is the cash generator. Q2 2026 beat on both revenue and EPS, insider buying confirmed in September, consensus PT $36 implies ~84% upside. Primary risk: leverage.
Sum-of-Parts EV/EBITDA with segment-level multiples derived from peer median (ZBH, SNN, GMED, IART), adjusted for growth and margin profile. Implied blended multiple 7.8x within ±20% of peer-adjusted 8x. Cross-check vs P/E method ($36.2 → implied 10x fwd P/E) consistent with mid-cap orthopedic peers. Sensitivity ±1x = ±$7.5/sh. The multiple is already risk-adjusted for leverage and scale; no additional generic discount applied. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Reconstructive segment EV | 9.5x EV/EBITDA FY26E on $219M segment EBITDA (51% of $430M consolidated), 6-8% organic growth premium vs peer median 10x | +36.07 |
| Prevention & Recovery segment EV | 7.0x EV/EBITDA FY26E on $211M segment EBITDA (49% share), mature low-growth bracing/DJO, vs peer median 8x | +25.61 |
| Corporate overhead | -$30M unallocated corp EBITDA × 7.0x blended multiple | −3.64 |
| Net debt | ($36M cash − $1,297M total debt) / 57.67M shares, as of Q2 2026 | −21.86 |
| FV base case | Explicit sum of components above (36.07 + 25.61 − 3.64 − 21.86) | ≈ $36.18 |
Short interest sits in "moderate-high" territory (15-25% range). Days-to-cover 3.5 is relatively low — a positive Q3 catalyst could trigger meaningful short covering. No class action, SEC investigation, or short-seller report currently active; shorts appear to be positioned on fundamentals (leverage + growth deceleration thesis) rather than fraud/governance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue ($B) | 1.71 | 2.11 | 2.25 | 2.34 | $2.31–2.37B |
| Organic growth % | +4% | +5% | +6% | +5% | +4-6% |
| Adj EBITDA ($M) | 280 | 375 | 403 | 430 | $425–435M |
| Adj EBITDA margin | 16.4% | 17.8% | 17.9% | 18.4% | — |
| Adj EPS ($) | 2.65 | 3.05 | 3.30 | 3.63 | $3.52–3.73 |
| GAAP net income ($M) | -172 | -110 | -1,184 | ~-20 to +40 | — |
| Net debt ($M) | 1,215 | 1,250 | 1,260 | ~1,200 | — |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 566.2 | 555.3 | 579.1 | 561.4 | 582.8 |
| Organic growth YoY | +6% | +5% | +6% | +6% | +5% |
| Adj EBITDA ($M) | 91.2 | 95.5 | 105.3 | 99.8 | 104.3 |
| Adj EBITDA margin | 16.1% | 17.2% | 18.2% | 17.8% | 17.9% |
| Adj EPS ($) | 0.72 | 0.78 | 0.86 | 0.84 | 0.90 |
| Cash EOP ($M) | 42 | 48 | 36 | 18 | 13 |
Business model — Two-segment orthopedic franchise
Reconstructive ~$1,165M FY26E (~50% rev) 🟢 ramping Knee, hip, shoulder, foot & ankle implants. Lima acquisition integrated. Organic +6-8%, driven by foot & ankle leadership and shoulder platform. EBITDA margin ~18-19%. Main risk: competitive pressure from ZBH, SYK, SNN. Prevention & Recovery ~$1,170M FY26E (~50% rev) 🟡 steady Bracing, casting, PT equipment, hot/cold therapy. DJO/Donjoy/Chattanooga brands. Organic +3-4%, mature category. EBITDA margin ~17-18%. Cash generator. Main risk: pricing pressure from private-label, DME reimbursement. Corporate / Unallocated -$30M FY26E EBITDA 🔴 overhead Corporate functions, strategic initiatives, legacy items. Opportunity for cost rationalization post-integration. Potential target for an activist case if strategic review surfaces.
Legal, regulatory and risk analysis
SWOT analysis
- +Deep-value multiple (fwd P/E 5.5x, EV/EBITDA 5.6x) vs peer median 11x / 10x
- +Profitable, scaled $2.3B revenue orthopedic franchise with 18% EBITDA margin
- +Reconstructive segment growing 6-8% organic — ahead of peer median
- +Insider buying March and September 2026 confirms management alignment
- +Strong Buy consensus (13 analysts), $36 PT = 84% upside
- −Elevated leverage: 2.9x net debt / EBITDA, $1,297M total debt vs $36M cash
- −$1.05B goodwill impairment in 2025 signals past overpayment on acquisitions
- −GAAP earnings persistently negative due to amortization and non-recurring items
- −P&R segment mature, low-single-digit growth drags blended narrative
- →Q3 2026 earnings Nov 5 as catalyst for multiple re-rating if guidance reaffirmed
- →Strategic review / potential P&R divestiture to unlock sum-of-parts value
- →Short covering (16.9% SI, 3.5 days-to-cover) on any positive surprise
- →Deleveraging path to <2.5x could trigger multiple expansion
- !Macro slowdown reducing elective procedure volumes
- !Refinancing risk if rates remain elevated through 2027
- !Competitive intensity from scaled peers (ZBH, SYK) in joint replacement
- !Further goodwill impairments if Lima integration under-delivers
Summary by assessment area
- Fwd P/E 5.5x and EV/EBITDA 5.6x — deep value vs peer median
- FV base $36.2 implies +85% upside; consensus $36.08 confirms independent estimate
- Downside anchored by $16.70 52W low (~15% below current)
- Net debt $1.26B / EBITDA 2.9x — above comfort zone but serviceable
- EBITDA growing $403M → $430M FY26E; FCF conversion 25%+
- No near-term debt maturity wall; refinancing risk if 10Y stays >5%
- Insider buying Mar & Sep 2026; no material selling in 12 months
- No class action, SEC investigation or short-seller report active
- Analyst consensus Moderate/Strong Buy; BMO upgrade July 2026
Sources: Enovis Q2 2026 press release (ir.enovis.com, SEC Form 8-K); StockAnalysis.com; MarketBeat; Benzinga; Yahoo Finance; SEC 10-Q 2026-07-03; BioSpace; MarketBeat Short Interest page (data as of Sep 15, 2026); Insidertrades.com Form 4 filings; peer data from Quantisnow/StockAnalysis. Market data — last verified close 2026-10-16: ENOV $19.59, market cap ~$1.13B, 52W: $16.70–$34.28, shares outstanding 57.67M. Short interest 16.94% (Sep 15, 2026). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.